A branch of the European Medicines Agency (EMA) has recommended expandingˡftrio਩vacaftor/tezacaftor/elexacaftor), in combination withˡlydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMAҳ Committee for Medicinal Products for Human Use (CHMP), now will be reviewed by the European Commission, [ŝThe post CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6 appeared first on Cystic Fibrosis News Today